

Supporting Information

Rec. Nat. Prod. X:X (2019) XX-XX

Alkaloid Profiling of *Hippeastrum* Cultivars by GC-MS, Isolation of Amaryllidaceae Alkaloids and Evaluation of Their Cytotoxicity

Latifah Al Shammari¹, Abdullah Al Mamun¹, Darja Koutová²,
Martina Majorošová², Daniela Hulcová^{1,3}, Marcela Šafratová³,
Kateřina Breiterová¹, Jana Maříková⁴, Radim Havelek² and
Lucie Cahlíková^{1,*}

¹*ADINACO Research Group, Department of Pharmaceutical Botany, Faculty of Pharmacy,
Charles University, Heyrovského 1203, 500 05 Hradec Kralove, Czech Republic*

²*Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University,
Simkova 870, Hradec Kralove 500 03, Czech Republic*

³*Department of Pharmacognosy, Faculty of Pharmacy, Charles University, Heyrovského 1203,
500 05 Hradec Kralove, Czech Republic*

⁴*Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy, Charles University,
Heyrovského 1203, 500 05 Hradec Kralove, Czech Republic*

Table of Contents	Page
Materials and Methods	2
General experimental procedures	2
Plant materials	2
Preparation of alkaloidal extracts	3
GC-MS analysis of alkaloidal extracts	3
Isolation of Amaryllidaceae alkaloids	3
Isolation of montanine (1)	3
Isolation of vittatine (2)	4
Isolation of 11-hydroxyvittatine (3)	4
Isolation of lycorine (4)	4
Isolation of hippeastrine (5)	5
<i>In vitro</i> cytotoxicity study	5
Cell culture and culture conditions	5
Cell treatment	5
WST-1 cytotoxicity assay	5
Statistical analysis	6
Figure S1: EI-MS Spectrum of Montanine (1)	6
Figure S2: ¹ H-NMR (500 MHz, CDCl ₃) Spectrum of Montanine (1)	7
Figure S3: ¹³ C-NMR (125 MHz, CDCl ₃) Spectrum of Montanine (1)	7
Figure S4: EI-MS Spectrum of Vittatine (2)	8
Figure S5: ¹ H-NMR (500 MHz, CDCl ₃) Spectrum of Vittatine (2)	8
Figure S6: ¹³ C-NMR (125 MHz, CDCl ₃) Spectrum of Vittatine (2)	9

Figure S7: EI-MS Spectrum of 11-Hydroxyvittatine (3)	9
Figure S8: ¹ H-NMR (500 MHz, CDCl ₃) Spectrum of 11-Hydroxyvittatine (3)	10
Figure S9: ¹³ C-NMR (125 MHz, CDCl ₃) Spectrum of 11-Hydroxyvittatine (3)	10
Figure S10: EI-MS Spectrum of Lycorine (4)	11
Figure S11: ¹ H-NMR (500 MHz, CDCl ₃) Spectrum of Lycorine (4)	11
Figure S12: ¹³ C-NMR (125 MHz, CDCl ₃) Spectrum of Lycorine (4)	12
Figure S13: EI-MS Spectrum of Hippeastrine (5)	12
Figure S14: ¹ H-NMR (500 MHz, CDCl ₃) Spectrum of Hippeastrine (5)	13
Figure S15: ¹³ C-NMR (125 MHz, CDCl ₃) Spectrum of Hippeastrine (5)	13
Table S1: Cytotoxicity of montanine, vittatine and hippeastrine	14
Table S2: Sensitivity to the antiproliferative activities of montanine, vittatine and hippeastrine	14
Table S3: MS spectra of identified Amaryllidaceae alkaloids	15
Figure S16: Structures of identified Amaryllidaceae alkaloids in fresh bulbs of <i>Hippeastrum</i> cultivars	16
References	16

Materials and Methods

General Experimental Procedures

All solvents were treated by using standard techniques before use. All reagents were purchased from commercial sources (Sigma Aldrich, Czech Republic) and used without purification. The NMR spectra were obtained in CDCl₃, CD₃OD and DMSO at ambient temperature on a VNMR S500 (Varian) spectrometer operating at 500 MHz for ¹H and 125.7 MHz for ¹³C. Chemical shifts were recorded as δ values in parts per million (ppm) and were indirectly referenced to tetramethylsilane (TMS) via the solvent signal (CDCl₃ - 7.26 ppm for ¹H and 77.0 ppm for ¹³C; CD₃OD - 3.30 ppm for ¹H and 49.0 ppm for ¹³C; DMSO - 2.49 ppm for ¹H and 39.7 ppm for ¹³C). Coupling constants (*J*) are given in Hz. For unambiguous assignment of ¹H and ¹³C signals, 2D NMR experiments, namely gCOSY, gHSQC, gHMBC and NOESY, were conducted using standard parameter settings and standard pulse programs provided by the producer. The EI-MS of isolated alkaloids were obtained on an Agilent 7890A GC 5975 inert MSD operating in EI mode at 70 eV (Agilent Technologies, Santa Clara, CA, USA). A DB-5 column (30 m × 0.25 mm × 0.25 μ m, Agilent Technologies, USA) was used. The temperature program was: 100-180°C at 15°C/min, 1 min hold at 180°C, and 180-300°C at 5°C/min and 5 min hold at 300°C; detection range *m/z* 40-600. The injector temperature was 280°C. The flow-rate of carrier gas (helium) was 0.8 mL/min. A split ratio of 1:15 was used. TLC was carried out on Merck precoated silica gel 60 F254 plates. Compounds on the plate were observed under UV light (254 and 366 nm) and visualized by spraying with Dragendorff's reagent.

Plant Materials

The fresh bulbs of all *Hippeastrum* taxa (between 150 g - 250 g) were obtained from the herbal dealer Lukon Glads (Sadská, Czech Republic). The botanical identification was performed by Prof. L. Opletal, CSc. Voucher specimens are deposited in the herbarium of the Faculty of Pharmacy in Hradec Králové under the following numbers: *Hippeastrum* cv. Pretty Nymph CUFPH-16130/AL-569, *H.* cv. Artic Nymph CUFPH-16130/AL-574, *H.* cv. Daphne CUFPH-16130/AL-563, *H.* cv. Double King CUFPH-16130/AL-567, *H.* cv. Ferrari CUFPH-16130/AL-562, and *H.* cv. Spartacus CUFPH-16130/AL-570.

Preparation of Alkaloidal Extracts

Fresh bulbs (3 x 15 g) were extracted 3 times with EtOH (50 mL) at room temperature for 24 h. The solvent was evaporated under reduced pressure and the residue dissolved in 2% HCl (10 mL). After removal of neutral compounds with diethyl ether (3 x 15 mL), the extract was basified with 10% NaHCO₃ and the alkaloids extracted with EtOAc (3 x 15 mL). The organic solvent was removed by evaporation. The dry alkaloid fraction (5 mg) was dissolved in MeOH to a final concentration of 1 mg/mL for further analysis. The isolation of montanine (**1**), vittatine (**2**), 11-hydroxyvittatine (**3**), lycorine (**4**), and hippeastrine (**5**) is described in detail in Supplementary Material. The isolated alkaloids were characterized by comparison of their MS, NMR, and additional physical properties with literature data [1-3]. The purity of all the isolated compounds was $\geq 95\%$ (Supplementary Material).

GC-MS Analysis of Alkaloidal Extracts

GC-MS analysis was performed on an Agilent 890A GC 5975 inert MSD operating in EI mode at 70 eV (Agilent Technologies, Santa Clara, CA, USA). The separation was carried out on a DP-5 MS column (30 m \times 0.25 mm \times 0.25 μ m, Agilent Technologies Santa Clara, CA, USA). The temperature program was from 100-150°C at 15°C/min, 1 min hold at 180°C and then 180°C-300°C at 5°C/min and a 35 min hold at 300°C. The injector temperature was 280°C. The flow rate of carrier gas (helium) was 0.8 mL/min. The detection range was m/z 35-600, and the detector temperature 200°C. An injection of 1 μ L of alkaloid solution (1 mg/mL) was introduced in split mode (split ratio 1:10). The individual alkaloids were identified based on comparison of their MS with those in the NIST library, with reported spectra in the literature, and finally with spectra of reference compounds isolated earlier in our laboratory. The confirmation of molecular weight was accomplished by a GCMS-QP2010 plus system with chemical ionization (Shimadzu, Japan). Isobutane (3.5; Linde Gas a.s. – Linde Technoplyn a.s., Czech Republic) was used as a reagent gas. The separation was carried out on a HP-5MS UI column (30 m \times 0.25 mm \times 0.25 μ m, Agilent Technologies Santa Clara, CA, USA) and the temperature gradient described above was used. The injector temperature was maintained at 280°C. The carrier gas (helium) flow rate was set at 0.8 mL/min. An injection of 1 μ L of alkaloid solution (1 mg/mL) was introduced in split mode (split 1:3) on the column. The samples were monitored over the full scan m/z 70-550. The detector temperature was kept at 200°C.

Isolation of Amaryllidaceae Alkaloids

*Isolation of Montanine (**1**)*

Montanine (**1**; 25 mg) was isolated from the alkaloidal extract of *Hippeastrum* cv. Pretty Nymph (265 g, 187 mg of extract) by preparative TLC (To:Et₂NH 9:1, three times). The structure was determined by comparison of its MS and NMR data, and additional physical properties with literature data [1]. The purity of the isolated compound was $\geq 95\%$.

¹H NMR (500MHz, CDCl₃) δ : 6.56 (1H, s), 6.47 (1H, s), 5.91–5.90 (1H, m), 5.88–5.87 (1H, m), 5.60–5.58 (1H, m), 4.36 (1H, d, $J = 16.6$ Hz), 4.12–4.09 (1H, m), 3.84 (1H, d, $J = 16.6$ Hz), 3.50–3.48 (1H, m), 3.48–3.45 (2H, m, overlapped), 3.45 (3H, s, overlapped), 3.33–3.31 (1H, m), 3.11 (1H, dd,

$J = 11.3$ Hz, $J = 2.4$ Hz), 3.05 (1H, d, $J = 11.3$ Hz), 2.24–2.17 (1H, m), 1.59 (1H, td, $J = 12.2$ Hz, $J = 3.5$ Hz)

^{13}C NMR (125MHz, CDCl_3) δ : 153.5, 146.8, 146.1, 132.2, 124.2, 113.2, 107.3, 106.8, 100.8, 79.6, 68.8, 60.7, 58.8, 57.6, 55.3, 45.5, 32.5

Isolation of Vittatine (2)

Vittatine (**2**; 12 mg) was isolated from the alkaloidal extract of *Hippeastrum* cv. Double King (191 g, 120 mg of extract) by preparative TLC (To:Et₂NH 9:1, two times). The structure was determined by comparison of its MS and NMR data, and additional physical properties with literature data [1]. The purity of the isolated compound was ≥ 95 %.

^1H NMR (500MHz, CDCl_3) δ : 6.85 (1H, s), 6.59 (1H, d, $J = 9.8$ Hz), 6.47 (1H, s), 5.67 (1H, dd, $J = 9.8$ Hz, $J = 5.3$ Hz), 5.90 (1H, d, $J = 8.3$ Hz, overlapped), 5.89 (1H, d, $J = 8.3$ Hz, overlapped), 4.37 (1H, d, $J = 17.0$ Hz, overlapped), 4.36–4.33 (1H, m, overlapped), 3.76 (1H, d, $J = 17.0$ Hz), 3.41–3.31 (2H, m), 2.93–2.85 (1H, m), 2.18 (1H, ddd, $J = 12.2$ Hz, $J = 9.3$ Hz, $J = 4.4$ Hz), 2.02–1.96 (1H, m), 1.91 (1H, ddd, $J = 12.2$ Hz, $J = 10.3$ Hz, $J = 5.8$ Hz), 1.74 (1H, td, $J = 13.7$ Hz, $J = 4.4$ Hz)

^{13}C NMR (125MHz, CDCl_3) δ : 146.1, 145.7, 138.4, 132.2, 127.5, 126.4, 107.0, 102.8, 100.7, 64.0, 62.8, 62.4, 53.6, 44.25, 44.22, 32.8

Isolation of 11-hydroxyvittatine (3)

11-Hydroxyvittatine (**3**; 12 mg) was isolated from the alkaloidal extract of *Hippeastrum* cv. Ferrari (218 g, 120 mg of extract) by preparative TLC (To:cHx:Et₂NH 45:50:5, three times). The structure was determined by comparison of its MS and NMR data, and additional physical properties with literature data [1]. The purity of the isolated compound was ≥ 95 %.

^1H NMR (500MHz, CDCl_3) δ : 6.85 (1H, s), 6.48 (1H, s), 6.41 (1H, d, $J = 10.3$ Hz), 6.36 (1H, dd, $J = 10.3$ Hz, $J = 4.9$ Hz), 5.92–5.90 (2H, m), 4.42–4.38 (1H, m), 4.32 (1H, d, $J = 17.1$ Hz), 4.01–3.98 (1H, m), 3.69 (1H, d, $J = 17.1$ Hz), 3.43–3.36 (2H, m), 3.26 (1H, dd, $J = 14.0$ Hz, $J = 2.9$ Hz), 2.26 (1H, td, $J = 14.0$ Hz, $J = 4.4$ Hz), 1.95–1.90 (1H, m)

^{13}C NMR (125MHz, CDCl_3) δ : 146.5, 146.3, 135.1, 134.2, 126.9, 126.7, 106.9, 103.2, 100.9, 80.1, 64.2, 63.5, 62.3, 61.4, 50.1, 32.3

Isolation of Lycorine (4)

Lycorine (**4**, 35 mg) was isolated from the alkaloidal extract of *Hippeastrum* cv. Artic Nymph (256 g, 187 mg of extract) by preparative TLC (To:EtOH:Et₂NH 7:2:1, two times). The structure was determined by comparison of its MS and NMR data, and additional physical properties with literature data [2]. The purity of the isolated compound was ≥ 95 %.

^1H NMR (500MHz, DMSO) δ : 6.80 (1H, s), 6.67 (1H, s), 5.95–5.93 (2H, m), 5.38–5.35 (1H, m), 4.87 (1H, d, $J = 5.3$ Hz), 4.76 (1H, d, $J = 3.8$ Hz), 4.28–4.25 (1H, m), 4.01 (1H, d, $J = 14.0$ Hz), 3.99–3.95 (1H, m), 3.35–3.32 (1H, m, overlapped), 3.32 (1H, d, $J = 14.0$ Hz, overlapped), 3.21–3.16 (1H, m), 2.60 (1H, d, $J = 10.5$ Hz), 2.53–2.37 (1H, m), 2.20 (1H, dd, $J = 17.3$ Hz, $J = 8.6$ Hz)

^{13}C NMR (125MHz, DMSO) δ : 145.8, 145.4, 141.8, 129.9, 129.8, 118.7, 107.2, 105.2, 100.7, 71.9, 70.4, 61.0, 56.9, 53.5, 40.3, 28.3

Isolation of Hippeastrine (5)

Hippeastrine (**5**, 15 mg) was isolated from the alkaloidal extract of *Hippeastrum* cv. Daphne 175 g, 162 mg of extract) by preparative TLC (To:EtOH:Et₂NH 7:2:1, two times). The structure was determined by comparison of its MS and NMR data, and additional physical properties with literature data [3]. The purity of the isolated compound was $\geq 95\%$.

¹H NMR (500MHz, CD₃OD) δ : 7.41 (1H, s), 7.05 (1H, s), 6.11 (2H, s), 5.69–5.66 (1H, m), 4.59–4.57 (1H, m), 4.28–4.25 (1H, m), 3.18 (1H, ddd, $J = 9.8$ Hz, $J = 8.2$ Hz, $J = 2.3$ Hz), 2.88 (1H, dd, $J = 9.8$ Hz, $J = 2.3$ Hz), 2.66–2.49 (3H, m), 2.36–2.30 (1H, m), 2.05 (3H, s)

¹³C NMR (125MHz, CD₃OD) δ : 166.5, 153.8, 149.7, 145.3, 140.8, 120.2, 119.5, 110.2, 109.8, 103.9, 84.1, 68.3, 68.0, 57.1, 43.6, 40.8, 28.7

In Vitro Cytotoxicity Study

Cell Culture and Culture Conditions

Selected human tumor and non-tumor cell lines {Jurkat (acute T cell leukemia), MOLT-4 (acute lymphoblastic leukemia), A549 (lung carcinoma), HT-29 (colorectal adenocarcinoma), PANC-1 (pancreas epithelioid carcinoma), A2780 (ovarian carcinoma), HeLa (cervix adenocarcinoma), MCF-7 (breast adenocarcinoma), SAOS-2 (osteosarcoma) and MRC-5 (normal lung fibroblasts)} were purchased from either ATCC (Manassas, USA) or Sigma-Aldrich (St. Louis, USA) and cultured according to the provider's culture method guidelines. All cell lines were maintained at 37 °C in a humidified 5% carbon dioxide and 95% air incubator. Cells in the maximum range of either 10 passages for the primary cell line (MRC-5), or 20 passages for the cancer cell lines (Jurkat, MOLT-4, A549, HT-29, PANC-1, A2780, HeLa, MCF-7 and SAOS-2) and in an exponential growth phase were used for this study.

Cell Treatment

All the alkaloids evaluated and doxorubicin, used as positive control, were dissolved in dimethyl sulfoxide – DMSO (Sigma-Aldrich, St. Louis, USA) to prepare stock solutions with a concentration of 10 - 50 mM based on their solubility. Stock solutions were freshly prepared before use in the experiments. For the experiments, the stock solutions were diluted with the appropriate culture medium to create final concentrations (10 μ M for a single-dose alkaloid cytotoxicity screen and 1 μ M for doxorubicin, used as a reference compound) making sure that the concentration of DMSO was < 0.1 % to avoid toxic effects on the cells. Control cells were sham-treated with a DMSO vehicle only (0.1 %; control).

WST-1 Cytotoxicity Assay

The WST-1 (Roche, Mannheim, Germany) reagent was used to determine the cytostatic effect of the test compounds. WST-1 is designed for the spectrophotometric quantification of cell proliferation, growth, viability and chemosensitivity in cell populations using a 96-well-plate format (Sigma, St.Louis, MO, USA). The principle of WST-1 is based on photometric detection of the reduction of tetrazolium salt to a colored formazan product. The cells were seeded at a previously

established optimal density (30000 Jurkat, 25000 MOLT-4, 500 A549, 1500 HT-29, 2000 PANC-1, 5000 A2780, 500 HeLa, 1500 MCF-7, 2000 SAOS-2 and 2000 MRC-5 cells/well) in 100 μ L of culture medium, and adherent cells were allowed to reattach overnight. Thereafter, the cells were treated with 100 μ L of either corresponding alkaloids or doxorubicin stock solutions to obtain the desired concentrations and incubated in 5% CO₂ at 37 °C. WST-1 reagent diluted 4-fold with PBS (50 μ L) was added 48 hours after treatment. Absorbance was measured after 3 hours incubation with WST-1 at 440 nm. The measurements were performed in a Tecan Infinite M200 spectrometer (Tecan Group, Männedorf, Switzerland). All experiments were performed at least three times with triplicate measurements at each drug concentration per experiment. The viability was quantified according to the following formula: (%) viability = (A_{sample} - A_{blank}) / (A_{control} - A_{blank}) x 100, where A is the absorbance of the employed WST-1 formazan measured at 440 nm. The viability of the treated cells was normalized to the viability of cells treated with 0.1 % DMSO (Sigma-Aldrich, St.Louis, MO, USA) as a vehicle control.

Statistical Analysis

The descriptive statistics of the results were calculated and the charts made in either Microsoft Office Excel 2010 (Microsoft, Redmond, WA, USA) or GraphPad Prism 5 biostatistics (GraphPad Software, La Jolla, CA, USA). In this study, all of the values were expressed as arithmetic means with SD of triplicates (n = 3), unless otherwise noted. The significant differences between the groups were analyzed using the Student's t-test and a P value \leq 0.05 was considered statistically significant.




Figure S1: EI-MS Spectrum of Montanine (1)

```

SAMPLE          PRESATURATION
date Apr 5 2019 satmode n
solvent cdcl3  wet      n
file /home/vnmr1/v~ SPECIAL
nmrSYS/data/Lucie/~ temp 25.0
Hippeastrum/HF-2-2- gain 38
/HF-2-2_H.fid spin 20
ACQUISITION    hst      0.008
sw 8012.8      pw90     8.800
at 2.045      alfa     10.000
np 32768      FLAGS
fb 4000      il        n
bs 32        in        n
d1 1.000     dp        y
nt 8         hs        nn
ct 8         PROCESSING
TRANSMITTER    fn      not used
tn H1        DISPLAY
sfrq 499.866  sp      337.2
tof 499.9    wp      3515.4
tpwr 60      rfl     1007.2
pw 4.400    rfp      0
DECOUPLER     rp      81.6
dn C13      lp      0
dof 0        PLOT
dm mnn      wc      175
decwave W40_OneNMR- sc 8
_W018 vs     43
dpwr 37     th      7
dmf 32258  ai cdc ph

```




Figure S2: $^1\text{H-NMR}$ (500 MHz, CDCl_3) Spectrum of Montanine (1)

```

SAMPLE          PRESATURATION
date Apr 5 2019 satmode n
solvent cdcl3  wet      n
file exp       SPECIAL
ACQUISITION    temp 25.0
sw 31250.0     gain 30
at 1.049      spin 20
np 65536      hst      0.008
fb 17000     pw90     11.300
bs 1         alfa     10.000
d1 1.000     FLAGS
nt 10000    il        n
ct 1400     in        n
TRANSMITTER    dp        y
tn C13      hs        nn
sfrq 125.705 PROCESSING
tof 1913.9   lb      1.50
tpwr 55      fn      not used
pw 5.650     DISPLAY
DECOUPLER     sp      3671.9
dn H1        wp      16202.9
dof 0        rfl     11480.3
dm yyy      rfp     9678.2
decwave w    rp      46.4
dpwr 40     lp      0
dmf 10870   PLOT
wc 175
sc 8
vs 50
th 2
nm cdc ph

```




Figure S3: $^{13}\text{C-NMR}$ (125 MHz, CDCl_3) Spectrum of Montanine (1)

Qualitative Plot Window Report




Figure S4: EI-MS Spectrum of Vittatine (2)

```

SAMPLE          PRESATURATION
date   Jan 16 2019  satmode      n
solvent  cdcl3      wet         n
file /home/vnmr1/v-
nmr/sys/data/Lucie/- temp      25.0
Hippeastrum/HF-3-k- gain      40
rystalyl/HF-3-kryat- spin     20
aly_H.fid hst         0.008
ACQUISITION    pw90      8.800
sw            8012.8  alfa    10.000
at            2.045
np            32768  il         n
fb            4000  in         n
bs            32    dp         y
dl            1.000  hs         nn
nt            8
ct            8    fn  not used
TRANSMITTER    DISPLAY
tn            H1    sp      758.2
sfrq         499.866  wp    2994.0
tof          499.8  rfl    1007.3
tpwr         60    rfp     0
pw          4.400  xp    -68.2
DECOUPLER     lp     0
dn            C13
dof           0    wc     175
dm            nnn  sc      8
decwave W40_OneNMR- vs     32
_w018        th     7
dpwr         37    ai  cdc  ph
dmf          32258
    
```




Figure S5: ¹H-NMR (500 MHz, CDCl₃) Spectrum of Vittatine (2)


```

SAMPLE          PRESATURATION
date            Jan 16 2019  satmode      n
solvent         cdcl3         wet       n
file /home/vnmr1/v~ SPECIAL
nmrsys/data/Lucie/~ temp      25.0
Hippeastrum/HF-3-k gain      30
rystaly/HF-3-kryst~ spin     20
aly_C.fid      hat          0.008
ACQUISITION    pw90        11.300
sw             31250.0     alfa      10.000
at            1.049      FLAGS
np           65536      il         n
fb           17000      in         n
bs            1        dp         y
dl           1.000      hs         nn
nt            500      PROCESSING
ct            500      lb         1.50
TRANSMITTER    fn          not used
tn            C13      DISPLAY
sfrq         125.705   sp         3596.6
tof          1913.9   wp         15409.5
tpwr         55      rfl         11479.4
pw           5.650   rfp         9678.2
DECOUPLER     rp         -63.1
dn            H1      lp         0
dof           0      PLOT
dm            yyy     wc         175
decwave       w      sc         8
dpwr          40     vs         29
dmf           10870   th         2
nm            cdc     ph

```




Figure S6: ¹³C-NMR (125 MHz, CDCl₃) Spectrum of Vittatine (2)

1-Hydroxy

Qualitative Plot Window Report




Figure S7: EI-MS Spectrum of 11-Hydroxyvittatine (3)

```

SAMPLE          PRESATURATION
date Feb 7 2019 satmode      n
solvent cdc13  wet          n
file /home/vnmr1/v-        SPECIAL
nmrSYS/data/Lucie/- temp    25.0
Hippeastrum/HF-8-1- gain    44
/HF-8-1_H.fid spin        20
ACQUISITION      hst        0.008
sw 8012.8 pw90      8.800
at 2.045 alfa      10.000
np 32768          FLAGS
fb 4000 il        n
bs 32 in          n
dl 1.000 dp        y
nt 8 hs          nn
ct 8             PROCESSING
TRANSMITTER      fn        not used
tn H1           DISPLAY
sfrq 499.866 sp    399.7
tof 499.8 wp     3395.6
tpwr 60 rfl      1007.3
pw 4.400 rfp     0
DECOUPLER        rp      -116.0
dn C13 lp        0
dof 0           PLOT
dm nnn wc       175
decwave W40_OneNMR~ sc     8
_W018 vs        25
dpwr 37 th       7
dmf 32258 ai cdc ph

```




Figure S8: $^1\text{H-NMR}$ (500 MHz, CDCl_3) Spectrum of 11-Hydroxyvittatine (3)

```

SAMPLE          PRESATURATION
date Feb 7 2019 satmode      n
solvent cdc13  wet          n
file /home/vnmr1/v-        SPECIAL
nmrSYS/data/Lucie/- temp    25.0
Hippeastrum/HF-8-1- gain    30
/HF-8-1_C.fid spin        20
ACQUISITION      hst        0.008
sw 31250.0 pw90     11.300
at 1.049 alfa      10.000
np 65536          FLAGS
fb 17000 il        n
bs 1 in           n
dl 1.000 dp        y
nt 5000 hs        nn
ct 2348          PROCESSING
TRANSMITTER      lb        3.00
tn C13           fn        not used
sfrq 125.705 sp    1876.2
tof 1913.9 wp     17171.9
tpwr 55 wp        11478.4
pw 5.650 rfl      9678.2
DECOUPLER        rp      -137.9
dn H1 lp         0
dof 0           PLOT
dm yyy          wc       175
decwave w wc    175
dpwr 40 sc     8
dmf 10870 vs    93
nm cdc ph      2

```




Figure S9: $^{13}\text{C-NMR}$ (125 MHz, CDCl_3) Spectrum of 11-Hydroxyvittatine (3)

Lyc

Qualitative Plot Window Report




Figure S10: EI-MS spectrum of Lycorine (4)

```

SAMPLE          PRESATURATION
date Mar 25 2011 satmode      n
solvent dms0 wet             n
file /home/vnmr1/v-         SPECIAL
nmrsys/data/Zaloha2016/L-   temp      not used
/2016/Zaloha2016/L-       gain      not used
ucie/Zephyranthes_~      spin       20
robusta/AK-11/AK-1-      hst       0.008
1_H.fid pw90             8.700
ACQUISITION  alfa         10.000
sw 3531.1          FLAGS
at 2.320          il      n
np 16384          in      n
fb 4000           dp      y
bs 32            hs      nn
d1 1.000          PROCESSING
nt 8             fn      not used
ct 8             DISPLAY
TRANSMITTER      sp         1011.0
tn H1            wp         2450.9
sfrq 499.869     rfl       999.1
tof -494.2       rfp       1244.7
tpwr 60          rp        -94.2
pw 4.350         lp         0
DECOUPLER        PLOT
dn C13           wc         175
dof 0           sc         8
dm nnn          vs         46
decwave W40_OneNMR th       7
dpwr 39         nm cdc ph
dmf 32258
  
```




Figure S11: ¹H-NMR (500 MHz, CDCl₃) Spectrum of Lycorine (4)




Figure S12: ^{13}C -NMR (125 MHz, CDCl_3) Spectrum of Lycorine (4)

HIPP

Qualitative Plot Window Report




Figure S13: EI-MS spectrum of Hippeastrine (5)




Figure S14: ^1H -NMR (500 MHz, CDCl_3) Spectrum of Hipppeastrine (5)




Figure S15: ^{13}C -NMR (125 MHz, CDCl_3) Spectrum of Hipppeastrine (5)

Table S1. Cytotoxicity of montanine, vittatine and hippeastrine following a single-dose exposure at a concentration of 10 μ M. Doxorubicin at 1 μ M was used as a reference drug. Data are shown as mean values \pm SD of at least three independent experiments and are expressed as percent of proliferation of 0.1% DMSO mock treated control cells (100 %)

Cell line/alkaloid	Montanine	Vittatine	Hippeastrine	Doxorubicin
Jurkat	4 \pm 1	91 \pm 3	40 \pm 1	2 \pm 0
MOLT-4	2 \pm 1	92 \pm 12	50 \pm 20	0 \pm 0
A549	23 \pm 2	80 \pm 4	69 \pm 4	11 \pm 5
HT-29	36 \pm 3	84 \pm 5	66 \pm 5	47 \pm 4
PANC-1	29 \pm 5	84 \pm 4	84 \pm 5	78 \pm 3
A2780	26 \pm 7	98 \pm 5	50 \pm 10	5 \pm 1
HeLa	18 \pm 2	100 \pm 5	86 \pm 5	11 \pm 6
MCF-7	12 \pm 2	79 \pm 2	70 \pm 21	37 \pm 3
SAOS-2	25 \pm 4	79 \pm 6	83 \pm 2	17 \pm 5
MRC-5	22 \pm 11	83 \pm 8	69 \pm 10	29 \pm 3

Table S2. Sensitivity to the antiproliferative activities of montanine, vittatine and hippeastrine following a single-dose exposure at a concentration of 10 μ M. Doxorubicin at 1 μ M was used as a reference drug^{a,b}.

Compound	Mean GP ^a	Range of GP ^b	Most sensitive cell lines	% inhibition
Montanine (1)	20	2 - 36	MOLT-4, Jurkat, MCF-7	2, 4, 12
Vittatine (2)	87	79 - 100	MCF-7, SAOS-2, A549	79, 79, 80
Hippeastrine (5)	67	40 - 86	Jurkat, MOLT-4, A2780	40, 50, 50
Doxorubicin	24	0 - 78	MOLT-4, Jurkat, A2780	0, 2, 5

^aMean growth percent (GP) value was calculated for each compound as an average of 9 cell lines proliferation in percent. ^bRange of growth percentage, as well as the three most sensitive cell lines with growth percentage values are indicated for each compound.

Table S3. MS spectra of identified Amaryllidaceae alkaloids

Alkaloid	RI^a	[M⁺] and characteristic ions <i>m/z</i>	Ref. for MS and RI data
Ismine	2278	257(28), 239(10), 238(100), 225(7), 211(7), 196(10), 180(8), 139(10)	[4]
Trisphaeridine	2284	223(100), 222(38), 193(4), 164(15), 138(28), 111(14)	[4]
Galanthamine	2408	287(90), 286(100), 270(20), 244(30), 230(5), 216(45), 174(30), 115(15)	c,d
Lycoramine	2442	289(60), 288(100), 232(10), 202(15), 187(15), 159(10), 115(20)	c,d
Vittatine/crinine*	2498	271(100), 228(25), 199(90), 187(80), 173(30), 128(30), 115(35), 56(20)	c,d
A1	2518	303(100), 288(15), 272(55), 260 (12), 242(23), 230 (20), 217(65), 202(25)	
9- <i>O</i> -Demethyllycosinine B	2575	283(100), 256(11), 255(70), 254(72), 240(30), 239(15), 223(10), 222(30), 210(10), 194(15),	[5]
11,12-Dehydroanhydrolycorine	2604	249(60), 248(100), 190(25), 163(10), 123(5), 95(15)	[4]
A2 Homolycorine type	2609	345(5), 286(4), 248(3), 177(5), 109(100), 108(21), 94(15), 43(15)	
Montanine	2615	301(100), 270(88), 257(35), 252(25), 229 (28), 226(30), 223(30), 199(20), 185(35), 115(20)	c,d
Haemanthamine	2640	301(15), 272(100), 240(15), 225(5), 211(15), 128(10)	c,d
Tazettine/Pretazzenine*	2655	331(20), 316(20), 298(25), 247(100), 230(10); 201(15); 181(10), 152(8)	c,d
Panracine	2719	287(100), 286(23), 270(20), 243(26), 223(30), 214(25), 199(30), 185(41), 128(20), 115(25)	c,d
11-Hydroxyvittatine	2736	287(5), 258 (100), 211(15), 186(20), 181(23), 153(13), 128(25), 115(25)	c
Lycorine	2749	287(35), 286(30), 268(20), 250(15), 227(70), 226(100), 211(8), 147(15)	c,d
Homolycorine	2769	315(<1), 206(<1), 178(2), 109(100), 150(1), 108(23), 94(3), 82(3)	c
3-Epimacronine	2813	329(30), 314(25), 245(100), 225(15), 201(80), 139(10)	c,d
Pseudolycorine	2823	289(25), 270(21), 252(14), 228(100), 214(10), 147(20), 111(20), 82(10)	[6]
Hippeastrine	2918	315(-), 162(4), 134(4), 125(100), 96(36), 82(3)	c
A3	3012	331(19), 330(20), 271(89), 270(100), 254(60), 252(65), 242(22), 229(34), 228(69), 210(18), 147(19), 91(13)	

*Cannot be distinguished by GC-MS; ^aFor GC conditions see Experimental section;




Figure S16: Structures of identified Amaryllidaceae alkaloids in fresh bulbs of *Hippeastrum* cultivars

References:

- [1] C. Muegge, B. Schablinski, K. Obst and W. Döpke (1994). Alkaloids from *Hippeastrum* hybrids, *Pharmazie* **49**, 444-447.
- [2] K. Likhitwitayawuid, C.K. Angerhofer, H. Chai, J.M. Pezzuto and G.A. Cordell (1993). Cytotoxic and antimalarial alkaloids from the bulbs of *Crinum amabile*, *J. Nat. Prod.* **56**, 1331-1338.
- [3] P.W. Jeffs, A. Abou-Donia, D. Campau and D. Staiger (1985). Alkaloids of the Amaryllidaceae. 27. Structures of 9-*O*-demethylhomolycorine and 5- α -hydroxyhomolycorine. Alkaloids of *Crinum defixum*, *C. scabrum*, and *C. latifolium*. Assignment of aromatic substitution patterns from ^1H -coupled carbon- ^{13}C spectra, *J. Org. Chem.* **50**, 1732-1737.

- [4] J.P. de Andrade, R.B. Giordani, L. Torras-Claveria, N.B. Pigni, S. Berkov, M. Font-Bardia, T. Calvet, E. Konrath, K. Bueno, L.G. Sachett, J.H. Dutilh, W. de Souza Borges, F. Viladomat, A.T. Henriques, J.J. Nair, J.A.S. Zuanazzi and J. Bastida (2016). The Brazilian Amaryllidaceae as a source of acetylcholinesterase inhibitory alkaloids, *Phytochem. Rev.* 15, 147-160.
- [5] Y. Guo, J.P. de Andrade, NB. Pigni, L. Torras-Claveria, L. R. Tallini, W. de S. Borges, F. Viladomat, J.J. Nair, J.A.S. Zuanazzi and J. Bastida (2016). New alkaloids from *Hippeastrum papilo* (RAVENNA) VAN SCHEEPEN, *Helv. Chim. Acta* **99**, 143-147.
- [6] R.L. Tallini, J. Bastida, N. Cortes, H.E. Osorio, C. Theoduloz and G. Schmeda-Hirschmann (2019). Cholinesterase inhibition activity, alkaloid profiling and molecular docking of Chilean *Rhodophiala* (Amaryllidaceae), *Molecules* **23**, 1532/1-1532/27.